82,147 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by CX Institutional

CX Institutional acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 82,147 shares of the company's stock, valued at approximately $2,381,000. CX Institutional owned approximately 0.17% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth $38,000. Tower Research Capital LLC TRC grew its stake in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after purchasing an additional 424 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded up $0.39 during trading hours on Thursday, reaching $26.44. 506,968 shares of the company traded hands, compared to its average volume of 488,662. The firm's 50-day moving average is $24.63 and its 200-day moving average is $31.09. The stock has a market cap of $1.25 billion, a P/E ratio of 8.81, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96.

Analyst Ratings Changes

Several research analysts have recently issued reports on AMPH shares. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.